Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Heart shield? common drug may prevent radiation damage in breast cancer patients

NCT ID NCT05607017

First seen Apr 17, 2026 · Last updated May 23, 2026 · Updated 5 times

Summary

This early-phase study tested whether losartan, a common blood pressure medication, could prevent early heart damage caused by radiation therapy in breast cancer patients. Five women with left-sided breast cancer took losartan during their standard radiation treatment. Researchers used heart MRIs to look for changes in heart tissue and blood tests to measure markers of inflammation. The goal was to see if losartan could reduce the risk of future heart failure.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Massachusetts General Hospital Cancer Center

    Boston, Massachusetts, 02114, United States

Conditions

Explore the condition pages connected to this study.